Acorda Drug Results
The company Acorda recently announced some safety results from its big drug, Fampridine-SR. The study tested patients' heart rythymns when taking the drug. The results were good and shares of the company soared.
The drug is believed to improve walking in patients with multiple sclerosis. There is not evidence that it will have any effect on the overall prognosis of the disease - i.e, delaying disability. To me, this would be categorized as a symptom management treatment, which is much less exciting than some other areas of research. Still, for all those who have difficulty walking, having another option to help is huge.
It could be another product in our arsenal of drugs to treat this disease. Hopefully, trials will continue to go well.